POSTER: AML-110 Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results From the Revumenib Phase 2 AUGMENT-101 Study | Publicación